Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial


Por: Ortiz-Maldonado, V, Martinez-Cibrian, N, Alserawan, L, Español-Rego, M, Navarro-Velázquez, S, Albiol, N, Oliver-Caldés, A, Triguero, A, Herrero-Garcia, M, Gutiérrez-Herrero, S, Benitez-Ribas, D, Paciello, ML, Torrent, A, Delgado-Serrano, J, Sánchez-Castañón, M, Calderón, H, Mata, JJ, Sánchez-Salinas, A, Sáez-Peñataro, J, Sans-Pola, C, Calvo-Orteu, M, López-Corral, L, Kwon, M, Rifón, J, Charry, P, Alonso-Fernández, RA, Huguet, M, Blázquez-Goñi, C, Sánchez-Pina, JM, Sánchez, R, Rosa-Rosa, JM, Martinez-López, J, Blanquer, M, Ribera, JM, Urbano-Ispizua, A, Bachiller, M, Palau, L, Olesti, E, Calvo, G, Martin-Martin, L, Orfao, A, González-Navarro, EA, Domenech, G, Varea, S, Juan, ME, Delgado, J and Esteve, J

Publicada: 1 mar 2026
Resumen:
Background Varnimcabtagene autoleucel (var-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy with adaptive intra-patient dose escalation and was approved in Spain in 2021 for patients older than 25 years with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. We report activity and safety from var-cel's pivotal trial in this patient population. Methods This multicentre, single-arm, phase 2 trial was conducted at nine academic centres in Spain. Eligible patients had CD19+ B-cell precursor acute lymphoblastic leukaemia in the first relapse or refractory disease, either ineligible for allogeneic haematopoietic cell transplantation (HCT) or with relapsed disease after allogeneic HCT; centralised measurable disease in peripheral blood or bone marrow, or both, using flow cytometry; were aged 18-70 years; and had an Eastern Cooperative Oncology Group performance status of 0-2. Patients received a single course of intravenous lymphodepleting chemotherapy with fludarabine (30 mg/m2 per day for 3 days) plus cyclophosphamide (300 mg/m2 per day for 3 days), followed by intravenous fractionated var-cel escalation (0 & centerdot;1, 0 & centerdot;3, 0 & centerdot;6, and 2 & centerdot;0 & times; 106 CART cells per kg) separated by at least 24 h, with each fraction contingent on safety criteria. The primary endpoint was complete response with undetected measurable residual disease (MRD; sensitivity of <= 10-5) determined by flow cytometry by day 28 from var-cel administration, assessed in the efficacy population (defined as all patients who received at least one var-cel fraction). Safety was analysed in patients that initiated lymphodepletion. This study is registered with ClinicalTrials.gov, NCT04778579 (completed). Findings Between May 19, 2021, and July 6, 2023, 50 patients were assessed for eligibility, 12 were ineligible, and 38 were enrolled. 37 (97%) of 38 underwent leukapheresis (ITT population), 33 (87%) initiated lymphodepleting chemotherapy (safety population), and 32 (84%) received at least one var-cel fraction (efficacy population). Five patients who underwent leukapheresis did not receive var-cel due to rapid disease progression (n=3), death due to venooclusive disease (n=1), and persistent COVID-19 (n=1). Patients receiving var-cel had a median age of 40 years (33-48); of whom, 16 (50%) were female and 16 (50%) were male. By data cutoff (Jan 18, 2024), the median follow-up from infusion was 8 & centerdot;6 months (IQR 5 & centerdot;1-14 & centerdot;4) and 27 (84 & centerdot;4% [95% CI 67 & centerdot;2-94 & centerdot;7]) of 32 patients who received at least one dose of var-cel had a complete response with undetected MRD by day 28. Treatment-emergent adverse events occurred in 31 (94%) of 33 patients. The most common grade 3 or higher adverse events were neutropenia in 15 (45%) patients, thrombocytopenia in seven (21%), anaemia in five (15%), and cytokine release syndrome in four (12%). Immune effector cell-associated neurotoxicity syndrome and cerebral oedema was observed in one patient (3%; grade >= 3), and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome occurred in two (6%; one resulted in death after protocol violation due to infusion during uncontrolled sepsis). Interpretation Var-cel induced deep remissions with low incidence of severe cytokine release syndrome and any-grade immune effector cell-associated neurotoxicity syndrome, supporting fractionated dose escalation as a strategy that preserves activity, limits acute toxic effects, and supports a hospital-based approach that could expand access to CAR T-cell therapy.

Filiaciones:
Ortiz-Maldonado, V:
 Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

Martinez-Cibrian, N:
 Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

Alserawan, L:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Español-Rego, M:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Navarro-Velázquez, S:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

Albiol, N:
 Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

Oliver-Caldés, A:
 Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain

Herrero-Garcia, M:
 Univ Salamanca, Ctr Invest Canc, Salamanca, Spain

 Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain

 Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain

 Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain

 Univ Salamanca, Dept Med, Salamanca, Spain

Gutiérrez-Herrero, S:
 Univ Salamanca, Ctr Invest Canc, Salamanca, Spain

 Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain

 Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain

 Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain

 Univ Salamanca, Dept Med, Salamanca, Spain

Benitez-Ribas, D:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Paciello, ML:
 Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain

Torrent, A:
 Hosp Germans Trias i Pujol, Inst Oncol Badalona, Dept Clin Haematol, Badalona, Spain

 Univ Autonoma Barcelona, Barcelona, Spain

Delgado-Serrano, J:
 Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain

 Univ Seville, Consejo Super Invest Cient, Dept Hematol, Inst Biomed Sevilla,Univ Hosp Virgen del Rocio, Seville, Spain

Sánchez-Castañón, M:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Calderón, H:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Mata, JJ:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Sánchez-Salinas, A:
 Hosp Clin Univ Virgen de la Arrixaca, Dept Haematol, Inst Murciano Invest Biosanitaria Pascual Parrilla, Murcia, Spain

Sáez-Peñataro, J:
 Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

Sans-Pola, C:
 Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Calvo-Orteu, M:
 Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

López-Corral, L:
 Univ Salamanca, Ctr Invest Canc, Salamanca, Spain

 Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain

 Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain

 Univ Salamanca, Dept Med, Salamanca, Spain

 Hosp Univ Salamanca, Dept Haematol, Salamanca, Spain

Kwon, M:
 Hosp Gen Univ Gregorio Maranon, Dept Hematol, Madrid, Spain

 Univ Complutense Madrid, Gregorio Maranon Hlth Res Inst, Madrid, Spain

Rifón, J:
 Clin Univ Navarra, Dept Haematol, Pamplona, Spain

Charry, P:
 Hosp Clin Barcelona, Dept Haemotherapy & Haemostasis, Barcelona, Spain

Alonso-Fernández, RA:
 Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain

Huguet, M:
 Hosp Germans Trias i Pujol, Inst Oncol Badalona, Dept Clin Haematol, Badalona, Spain

 Univ Autonoma Barcelona, Barcelona, Spain

Blázquez-Goñi, C:
 Univ Seville, Consejo Super Invest Cient, Dept Hematol, Inst Biomed Sevilla,Univ Hosp Virgen del Rocio, Seville, Spain

Sánchez-Pina, JM:
 Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain

Sánchez, R:
 Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain

Rosa-Rosa, JM:
 Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain

Martinez-López, J:
 Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain

Blanquer, M:
 Hosp Clin Univ Virgen de la Arrixaca, Dept Haematol, Inst Murciano Invest Biosanitaria Pascual Parrilla, Murcia, Spain

:
 Hosp Germans Trias i Pujol, Inst Oncol Badalona, Dept Clin Haematol, Badalona, Spain

 Univ Autonoma Barcelona, Barcelona, Spain

 Josep Carreras Res Inst, Barcelona, Spain

Urbano-Ispizua, A:
 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

 Josep Carreras Res Inst, Barcelona, Spain

Bachiller, M:
 Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Palau, L:
 Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain

Olesti, E:
 Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

Calvo, G:
 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Martin-Martin, L:
 Univ Salamanca, Ctr Invest Canc, Salamanca, Spain

 Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain

 Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain

 Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain

 Univ Salamanca, Dept Med, Salamanca, Spain

 Carlos III Hlth Inst, Madrid, Spain

Orfao, A:
 Univ Salamanca, Ctr Invest Canc, Salamanca, Spain

 Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain

 Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain

 Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain

 Univ Salamanca, Dept Med, Salamanca, Spain

 Carlos III Hlth Inst, Madrid, Spain

González-Navarro, EA:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Domenech, G:
 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Med Stat Core Facil, Barcelona, Spain

Varea, S:
 Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Juan, ME:
 Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

Delgado, J:
 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

Esteve, J:
 Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain

 Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain

 Univ Barcelona, Barcelona, Spain

 Josep Carreras Res Inst, Barcelona, Spain
ISSN: 23523026





Lancet Haematology
Editorial
Lancet Publishing Group, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 13 Número: 3
Páginas: 133-143
WOS Id: 001711387200001
ID de PubMed: 41651004

MÉTRICAS